Skip to main content
Premium Trial:

Request an Annual Quote

BGI Extends Offer to Acquire Complete Genomics

NEW YORK (GenomeWeb News) – BGI-Shenzhen today said that it has extended its offer to acquire Complete Genomics for $3.15 per share.

The offer, with a total deal value of nearly $118 million, was scheduled to expire at midnight tonight, New York City time. It has now been extended to midnight on Wednesday, Nov. 21.

According to BGI, as of the close of business yesterday, approximately 6,731,897 shares had been validly tendered and not withdrawn from the offer. Complete Genomics has roughly 34.3 million total shares outstanding.

BGI launched its offer to merge with Complete Genomics in mid-September. Since the deal was announced, a handful of shareholder lawsuits have been filed against Complete Genomics, its board of directors, and executives seeking to block the deal.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.